In vitro transcriptomic responses to thioacetamide-S-oxide exposure in human primary hepatocytes, renal tube epithelial, and cardiomyocytes

In this study we tested the ability to predict organ injury endpoints from in vitro transcriptomics responses at early time points (9 and 24 hours) after to thioacetamide-S-oxide treatment, the toxic metabolite of thioacetamide. Thioacetamide, an organosulfur compound, have been extensively used in animal studies as a hepatotoxin and carcinogen for its ability to cause acute liver damage. Overall design: We treated three human cell types, primary hepatocytes (vehicle, low (0.50 mM), or high (0.25 mM) dose), renal tube epithelial cells (vehicle, low (0.25 mM), or high (1.00 mM) dose), and cardiomyocytes (vehicle, low (0.25 mM), or high (0.75 mM) dose) with thioacetamide-S-oxide. RNA-seq data were collected 9 and 24 hours after application of vehicle or thioacetamide-S-oxide.